Therapeutic activity of agonistic, human anti-CD40 monoclonal antibodies requires selective FcγR engagement - Dahan, R; Barnhart, B C; Li, F; Yamniuk, A P; Korman, A J; Ravetch, J V (Cancer Cell, 2016)